Climb Bio Shares Rise On CLYM116 Data Supporting Every-12-Week Dosing

Climb Bio (CLYM) reported positive initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, citing a prolonged half-life and deep, durable suppression of APRIL, IgA, and Gd-IgA1. While early-stage, the response durability profile is a meaningful efficacy signal that can support ongoing development expectations.